# Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

> **NCT00569946** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 64 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** AG-013736

## Key facts

- **NCT ID:** NCT00569946
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-12
- **Primary completion:** 2010-02-26
- **Final completion:** 2012-10-30
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2019-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00569946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00569946, "Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00569946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*